Facts on Overcoming Barriers to Access
-
VACCINES: Barriers to Access
The major barriers to access are high vaccine prices, inadequate financing for immunisation, and weakness of national immunisation systemsLast updated 27 July 2011
-
VACCINES: Pharmaceutical Companies Production
The new and most expensive vaccines continue to be produced by a handful of multinational pharmaceutical companies who charge high pricesLast updated 27 July 2011
-
VACCINES: Un-Immunised Children
26 million children – roughly one in five born each year – remained un-immunised globallyLast updated 27 July 2011
-
DR-TB: Treatment Regimen
A 24-month DR-TB treatment regimen can cost as much as US$9,000 for one patient – 475 times more than the $19 per patient it costs to cure standard, drug-sensitive TBLast updated 27 July 2011
-
DR-TB: Drug Price Increase
Prices for two DR-TB drugs have increased by more than 600% and one drug by more than 800% over the last decadeLast updated 27 July 2011
-
DR-TB: Treatment of New Cases
Less than 7% of 440,000 new DR-TB cases each year receive treatmentLast updated 27 July 2011
-
TB: Drug Price Increase
Prices for TB drugs have been increasing as some manufacturers put an end to subsidies that have kept prices lowerLast updated 27 July 2011
-
DR-TB: Access to Treatment
Of the 5 million people who developed DR-TB in the past decade, less than 1% had access to appropriate treatment & 1.5 million diedLast updated 27 July 2011
-
AIDS: 80% of ARVs from India
More than 80% of the AIDS medicines used to treat more than 5 million people across the developing world come from producers in IndiaLast updated 27 July 2011
-
HIV: Generic Drugs India
More than 80% of all donor-funded HIV medicine purchases for developing countries from 2003-2008 were for generic drugs from IndiaLast updated 27 July 2011
↑ To top
